Acute Arthritis/Osteomyelitis in Children
OSTEOMYELITIS IN CHILDREN: Osteomyelitis (OM) is defined as an infection of the bone marrow and adjacent osseous structures with potential surrounding soft tissue extent. It can occur at any age, generally in children 1 –16 years old. In children, it is predominantly caused by hematogenous spread of infection, typically bacterial. Generally, the metaphysis is involved. Transphyseal spread to the epiphysis and joint is rare but can occur in children younger than 18 months, or in older children with closed growth p lates, due to a different blood perfusion to the epiphysis. The first imaging modality of choice is conventional radiography (CR), but CR has limited sensitivity in early stages. Osseous destruction is evident only 10–14 days after the initial infection. In low-grade osteomyelitis, nonspecific sof t tissue swelling and subtle bone resorption or a lytic lesion at the metaphysis may be seen, as in more advanced stages, lytic bone destruction, and periosteal formation are seen. Magnetic resonance imaging (MRI) is the preferred modality for early detection of lesions. Brodie’s abscess is a subt ype of osteomyelitis typically seen in children, with intraosseous abscess formation (Figure 1). Another specific subtype of OM is chronic recurrent multifocal osteomyelitis (CRMO), which is characterized by multiple sterile inflammatory bone lesions with a relapsing and remitting course. Whole-body MRI is increasingly being used for evaluation. OM has a variable...
Conclusions: Temporal trends in opioid use in cancer patients depend on patient, demographic, and tumor characteristics. Overall, understanding these correlations may help physicians better identify patient-specific risks of opioid use and could help better inform future evidence-based, cancer-specific opioid prescription guidelines.
ConclusionLSD1 metabolically regulates osteoclastogenesis in an inflammatory energy-demanding environment and provides new therapeutic strategies targeting osteoclasts against inflammatory arthritis including RA.
AbstractBackgroundThis exploratory study investigates if intra-articular injected gold microparticles in knee osteoarthritis (KOA) reduce immunomodulatory-based pain via proteomic changes in the synovial fluid (SF) and serum.MethodsThirty patients with moderate KOA were included. Intraarticular injections with 20 mg gold microparticles (72.000 particles, 20-40 µm in diameter) using the patient’s synovial fluid (SF) as carrier were performed. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscores for pain, stiffness, and function were assessed at inclusion, 8 weeks and 2 years The PainD...
We present two cases of AOT, the first case concerns a 23-year-old patient with an AOT located in the maxilla and the second case involves a 37-year-old patient presenting an AOT with mandibular localization.
Medical research and development in the context of aging has, like all other medicine, been dominated for a long time by a model in which a single disease is identified by symptoms and then treated. In the context of infectious disease and inherited conditions, this is a good way to go about the matter of investigation, treatment, and assignment of resources. A patient typically has one disease at a time, and the symptoms are distinct and clearly caused by the disease in question. Indeed, the disease paradigm arose from the modern era's long road towards ever more effective control of infectious disease. The institutions a...
University of Pittsburgh researchers studied 14 patients with chronic plantar fasciitis - which can feel 'like a nail going right through their heel' - finding belly fat could help treat them.
Condition: Juvenile Idiopathic Arthritis Hip Intervention: Radiation: pelvic radiograph Sponsor: University Tunis El Manar Recruiting
Condition: Low Back Pain Interventions: Other: Manual Lymphatic Drainage and Hot Pack; Other: Hot Pack Sponsor: Riphah International University Not yet recruiting
Condition: Fabry Disease Interventions: Drug: Venglustat (GZ402671); Drug: Placebo Sponsor: Genzyme, a Sanofi Company Not yet recruiting
Condition: Low Back Pain Intervention: Other: ED Physical Therapy Sponsors: Northwestern University; Agency for Healthcare Research and Quality (AHRQ) Recruiting
More News: Acute Leukemia | Arthritis | Belgium Health | Bone Cancers | Bone Marrow Aspiration and Biopsy | Children | Chronic Leukemia | Chronic Pain | Disability | Ewing's Sarcoma | Fine Needle Aspiration | Haemophilia | Hematology | Hemophilia | Leukemia | MRI Scan | Osteomyelitis | Pain | Perfusion | Radiography | Radiology | Rheumatology | Sarcomas | Septic Arthritis